Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Meletios-Athanasios Dimopoulos

Showing results (261-270 of 283) with videos related to

Pageof 29
Sort By:
Annals of Hematology|October 1, 2015
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experienceEirini Katodritou, Evangelos Terpos, Efstathios Kastritis, et al.
Viruses|September 28, 2021
Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent PlasmaThomas P Thomopoulos, Margherita Rosati, Evangelos Terpos, et al.
Nature Communications|June 15, 2022
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomesMark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis, et al.
American Journal of Hematology|June 3, 2025
Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group on 175 PatientsEirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, et al.
Microorganisms|April 30, 2021
A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control AnalysisVasiliki Pappa, Anthi Bouchla, Evangelos Terpos, et al.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA StudySikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Msphere|June 30, 2021
Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission after Lifting of Travel Restrictions Based on Risk Assessment during Summer 2020Evangelia Georgia Kostaki, Georgios A Pavlopoulos, Kleio-Maria Verrou, et al.
The New England Journal of Medicine|June 4, 2024
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaThierry Facon, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Vaccines|April 3, 2021
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody ResponseOurania E Tsitsilonis, Dimitrios Paraskevis, Evi Lianidou, et al.
Pageof 29

Showing results (261-270 of 283) with videos related to

Sort By:
Pageof 29
Annals of Hematology|October 1, 2015
Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experienceEirini Katodritou, Evangelos Terpos, Efstathios Kastritis, et al.
Viruses|September 28, 2021
Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent PlasmaThomas P Thomopoulos, Margherita Rosati, Evangelos Terpos, et al.
Nature Communications|June 15, 2022
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomesMark Bustoros, Shankara Anand, Romanos Sklavenitis-Pistofidis, et al.
American Journal of Hematology|June 3, 2025
Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group on 175 PatientsEirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, et al.
Microorganisms|April 30, 2021
A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control AnalysisVasiliki Pappa, Anthi Bouchla, Evangelos Terpos, et al.
Blood Advances|January 7, 2026
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström MacroglobulinemiaSaurabh Zanwar, Jithma P Abeykoon, Shirley D'Sa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA StudySikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Msphere|June 30, 2021
Molecular Epidemiology of SARS-CoV-2 in Greece Reveals Low Rates of Onward Virus Transmission after Lifting of Travel Restrictions Based on Risk Assessment during Summer 2020Evangelia Georgia Kostaki, Georgios A Pavlopoulos, Kleio-Maria Verrou, et al.
The New England Journal of Medicine|June 4, 2024
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaThierry Facon, Meletios-Athanasios Dimopoulos, Xavier P Leleu, et al.
Vaccines|April 3, 2021
SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody ResponseOurania E Tsitsilonis, Dimitrios Paraskevis, Evi Lianidou, et al.
Pageof 29